BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 4, 2013
View Archived Issues
Results reported for volasertib plus low-dose cytarabine therapy in AML patients
Read More
Alize Pharma launches collaborative research program for AZP-531
Read More
Chroma receives milestone payment from GSK for HDAC inhibitor
Read More
Tumor-suppressing MAb demonstrates preclinical antitumor efficacy
Read More
BRD-9876 identified as potential therapeutic candidate in niche-based screening
Read More
Novel guanylate cyclase activators disclosed by Astellas Pharma
Read More
U.S. researchers present new protein kinase inhibitors
Read More
Receptos patents new GLP-1 receptor modulators
Read More
New pegylated nitroimidazole conjugates divulged by researchers in the U.S. and Taiwan
Read More
Novel DGAT1 inhibitors synthesized at Daiichi Sankyo
Read More
University of Tokushima discloses novel anticancer compounds
Read More
New MISRII antibodies presented by The Fox Chase Cancer Center
Read More
Swiss and U.S. scientists patent new agents for malaria and toxoplasmosis
Read More
Updated results presented from the GAUSS trial of AMG-145
Read More
Microbiotix enters licensing agreement for MBX-700 and MBX-701
Read More
TheraVida reports topline Tolenix data in overactive bladder and urinary incontinence
Read More
NGM signs agreement with Janssen for novel therapeutics for diabetes
Read More
Zogenix reports data from phase I Relday trial
Read More
FDA approves next-generation Xience Xpedition drug eluting stent system
Read More
PharmaEngine and BeBetter enter oncology collaboration
Read More
EPIRUS' BOW-015 shows bioequivalence to Remicade in phase I study
Read More
Phase I trial of mibefradil for cancer completed
Read More
Repligen and Pfizer sign worldwide licensing agreement for spinal muscular atrophy
Read More
Biogen's phase III trial of dexpramipexole in ALS fails to meet endpoints
Read More
Second phase IIa study of Z-160 begins for chronic neuropathic pain
Read More
Celtaxsys commences first-in-human study of treatment for pulmonary inflammation
Read More
Alnylam files application for phase I study of RNAi therapeutic in the U.K.
Read More